2000
Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans.
Varrone A, Fujita M, Verhoeff NP, Zoghbi SS, Baldwin RM, Rajeevan N, Charney DS, Seibyl JP, Innis RB. Test-retest reproducibility of extrastriatal dopamine D2 receptor imaging with [123I]epidepride SPECT in humans. Journal Of Nuclear Medicine 2000, 41: 1343-51. PMID: 10945525.Peer-Reviewed Original ResearchConceptsTest-retest variabilityTemporal cortexTest-retest reproducibilityOutcome measuresExtrastriatal regionsD2 receptorsPlasma clearanceExtrastriatal dopamine D2 receptorsGood test-retest variabilityConstant infusion paradigmExtrastriatal D2 receptorsDopamine D2 receptorsBrain radioactivityStriatal radioactivityHealthy volunteersReceptor densityInfusion rateParent tracerSPECT studiesLess test-retest variabilityCortexHigh test-retest variabilityFree fractionReceptor quantificationReceptors
1998
Significance of nonuniform attenuation correction in quantitative brain SPECT imaging.
Rajeevan N, Zubal IG, Ramsby SQ, Zoghbi SS, Seibyl J, Innis RB. Significance of nonuniform attenuation correction in quantitative brain SPECT imaging. Journal Of Nuclear Medicine 1998, 39: 1719-26. PMID: 9776276.Peer-Reviewed Original ResearchConceptsHealthy control subjectsHealthy human control subjectsHuman control subjectsControl subjectsDisease patientsGroup of patientsParkinson's disease patientsNonuniform attenuation correctionOutcome measuresParkinson's diseaseSPECT scansBrain SPECTBrain regionsDopamine transporterPatientsBackground activity ratioNonuniform attenuation mapGold standardModerate improvementScansBrain ROIsSPECT imagesAttenuation correctionDiseaseQuantitative brain SPECT